Companies › Hrain Biotechnology
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Human BCMA Targeted T Cells Injection (BCMA CAR-T) BCMA-targeted CAR-T cell therapy | BCMA | Phase 2 | Multiple Myeloma | Jul 2027 |
| Anti-Human CD70 T-Cell Injection Anti-CD70 CAR-T cell therapy | CD70 | Phase 1 | Renal Cell Carcinoma (RCC) | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05594797 | Human BCMA Targeted T Cells Injection (BCMA CAR-T) | Phase 2 | Multiple Myeloma | Oncology | Jul 2027 |
| NCT07647744 | Anti-Human CD70 T-Cell Injection | Phase 1 | Renal Cell Carcinoma (RCC) | Oncology | Jun 2029 |
Marzieh Ebrahimi Beijing Yongtai Ruike Biotechnology Company iCell Gene Therapeutics Hebei Senlang Biotechnology Hangzhou Converd
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.